Senior Scientist, Office of Chief Scientist
Office of Health Informatics, FDA
Dr. Boja leads the precisionFDA’s biomedical competitions around omics science, as well as outreach activities in building a community of scientists around the analysis of biological datasets to inform regulatory science and advance precision medicine. Prior to joining OHI, she was a Program Director at the Office of Cancer Clinical Proteomic Research, NCI, NIH, who provided scientific expertise and leadership in managing the Clinical Proteomic Tumor Analysis Consortium program.
Children's Brain Tumor Network Pediatric Brain Tumor Proteomics Pilot
Pediatric brain tumors are the leading cause of disease related death in children. Major factors contributing to treatment failures for children with brain tumors include: i) the lack of comprehensive molecular description of the disease and an associated dearth of integration of the tumors’ biologi
Craniopharyngioma, Medulloblastoma, HGG, (AT/RT), LGG, Ependymoma, Ganglioglioma, DNET, Schwannoma
Childhood craniopharyngiomas are rare tumors usually found near the pituitary gland (a pea-sized organ at the bottom of the brain that controls other glands) and the hypothalamus (a small cone-shaped organ connected to the pituitary gland by nerves).Craniopharyngiomas are usually part solid mass and
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature